Inflammation, immunity and development of essential hypertension

Journal of Hypertension

Volumn 32, Issue 2, 2014, Pages 228-229

  Schiffrin, Ernesto L ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN;

ADAPTIVE IMMUNITY; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; ESSENTIAL HYPERTENSION; FOLLOW UP; HUMAN; IMMUNE DYSREGULATION; IMMUNITY; INFLAMMATION; INNATE IMMUNITY; LEUKOCYTE COUNT; MACROPHAGE ACTIVATION; MEMORY T LYMPHOCYTE; METABOLIC SYNDROME X; NOTE; OBESITY; PREHYPERTENSION; PREVALENCE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

FEMALE; HUMANS; HYPERTENSION; LEUKOCYTOSIS; MALE; PREHYPERTENSION;

EID: 84892978572     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000042     Document Type: Note

References (20)

1. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events in apparently healthy women. Circulation 1998; 98:731-733.
2. Blake JH, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003; 108:2993-2999.
3. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289:1799-1804.
4. Barzilay JI, Abraham L, Heckbert SR. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes 2001; 50:2384-2389.
5. Savoia C, Schiffrin EL. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci 2007; 112:375-384.
6. Verlohren S, Muller DN, Luft FC, Dechend R. Immunology in hypertension, preeclampsia, and target-organ damage. Hypertension 2009; 54:439-443.
7. Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, et al. Inflammation, immunity and hypertension. Hypertension 2011; 57:132-140.
8. Subramanian S, Tawakol A, Burdo TH, Abbara S, Wei J, Vijayakumar J, et al. Arterial inflammation in patients with HIV. JAMA 2012; 308:379-386.
9. Schillaci G, Maggi P, Madeddu G, Pucci G, Mazzotta E, Penco G, et al., for the CISAI Study Group. Symmetric ambulatory arterial stiffness index and 24-h pulse pressure in HIV infection: results of a nationwide cross-sectional study. J Hypertens 2013; 31:560-567.
10. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens 2013; 31:433-443.
11. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med 2007; 204:2449-2460.
12. Viel EC, Lemarié CA, Benkirane K, Paradis P, Schiffrin EL. Immune regulation and vascular inflammation in genetic hypertension. Am J Physiol Heart Circ Physiol 2010; 298:H938-H944.
13. Barhoumi T, Kasal DAB, Li MW, Shbat L, Laurant P, Fritsch Neves M, et al. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension 2011; 57:469-476.
14. Julius S, Egan BM, Kaciroti NA, Nesbitt SD, Chen AK, for TROPHY investigators. In prehypertension leukocytosis is associated with body mass index but not with blood pressure or incident hypertension. J Hypertens 2014; 32:251-259.
15. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, et al., for the Trial of Preventing Hypertension (TROPHY) Study Investigators. Feasibility of treating prehypertension with an angio-tensin-receptor blocker. N Engl J Med 2006; 354:1685-1697.
16. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290:2945-2951.
17. Fliser D, Buchholz K, Haller H, and for the EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Anti-inflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microin-flammation. Circulation 2004; 110:1103-1107.
18. Touyz RM, Savoia C, He Y, Endemann D, Pu Q, Ko EA, et al. Increased inflammatory biomarkers in hypertensive type 2 diabetic patients: improvement after angiotensin II type 1 receptor blockade. J Am Soc Hypertens 2007; 1:189-199.
19. Gillum RF, Mussolino ME. White blood cell count and hypertension incidence: The NHANES I Epidemiologic Follow-up Study. J Clin Epidemiol 1994; 47:911-919.
20. Friedman GD, Selby JV, Quesenberry CP Jr. The leukocyte count: a predictor of hypertension. J Clin Epidemiol 1990; 43:907-911.